The US regulator has cleared the nalmefene nasal spray Opvee as an emergency treatment for individuals aged 12 or over who are suspected of having taken an overdose of natural or synthetic opioids.

The drug is called Opvee and was approved by the FDA in May of 2023 and is the first Nalmefene nasal spray to be approved. It is another step further in helping fight overdoses both from addiction ...

The award from the Biomedical Advanced Research and Development Authority (BARDA) will be used in part to create a stockpile of 200,000 doses of Opvee, the first nalmefene-based nasal spray to be ...

An alternative, nasal spray, formulation has been developed that demonstrates good efficacy, high tolerability and a very fast onset of action. This study assessed the pharmacokinetics and ...

In addition to 4mg Narcan nasal spray, the fund also provides 4mg Padagis ... Additional overdose reversal drugs such as Nalmefene are not currently supplied by the state, but folks working ...

The NDA submission is supported by results from a pharmacokinetic (PK) study comparing OPNT003 to an intramuscular nalmefene ... nasal nalmefene to NARCAN® (naloxone HCI) Nasal Spray 4mg in ...

In this study, the first to compare the pharmacokinetics, tolerability and safety of nasally and orally administered zolmitriptan in healthy Japanese subjects, zolmitriptan nasal spray 2.5 and 5mg ...